What Verb Biotics does

Verb Biotics is a private B2B microbiome health ingredient company founded in 2021 and headquartered in Boston, MA, with operations referenced in Boulder, CO. It develops and sells proprietary clinically validated biotic ingredients — GABA Probiotic LP815 (a Lactiplantibacillus plantarum strain producing gamma-aminobutyric acid for mood, stress, and sleep support) and Keystone Postbiotic (an oat-substrate postbiotic produced via precision fermentation targeting microbiome diversity, immunity, and healthy aging) — to food, beverage, dietary supplement, and pet health brands. Line extensions include LP815 for Women (tension and sleep support) and LP815 for Pets (canine anxiety and aggression support).

The company's technical platform is built on a "function-first" discovery approach: instead of optimizing for Colony Forming Units, Verb starts from a target health outcome and uses computational modeling, high-throughput screening, and whole-genome sequencing to identify strains with specific bioactive production capabilities and to verify safety (antibiotic resistance and toxin screening). Both lead ingredients are backed by randomized, placebo-controlled human trials — a 139-participant LP815 sleep/stress study and a 76-participant Keystone Postbiotic microbiome study — with LP815 results published in Nature Scientific Reports in January 2026. Products carry GRAS, Non-GMO Project Verified, and allergen-free certifications.

Verb's commercial model is direct enterprise sales to brand formulation teams, supplemented by participation at industry events such as SupplySide Global, content marketing through the VerbLABS hub, and PR around clinical milestones. Its revenue stream is best characterized as ingredient licensing/sales to brand partners, with quote-based, non-publicly-disclosed pricing. In March 2026 the company signed a strategic partnership with consumer healthcare company Opella to broaden distribution. The portfolio was expanded through the June 2023 acquisition of YSPOPIA Bioscience's health and wellness strains, and the R&D pipeline is augmented by a 2024 computational biology collaboration with Evogene and ongoing academic engagements such as with Prof. Siobhain O'Mahony (University College Cork) on the gut-brain-hormone axis.

Name

Verb Biotics

Legal name

Verb Biotics

Website

https://verbbiotics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Verb Biotics is a private B2B microbiome health ingredient company that designs, clinically validates, and sells proprietary probiotic and postbiotic ingredients — including GABA-producing LP815 and Keystone Postbiotic — to food, beverage, supplement, and pet health brands.

Ownership category

akta.pro rank

Product category

Microbiome Health Ingredients

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome-Derived Metabolite Therapeutics (postbiotics) (HLAAAFAB), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI), Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials) (AFADALAE)

Keywords

• Probiotic ingredients
• Postbiotic supplements
• Microbiome health
• Biotic manufacturing
• GABA probiotics

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Ingredient Sales to Brands: Verb Biotics sells its proprietary biotic ingredients (GABA Probiotic LP815 and Keystone Postbiotic) to food, beverage, and supplement brands for inclusion in their product formulations. The company positions as an ingredient supplier targeting functional food, beverage, and dietary supplement manufacturers seeking differentiated, clinically validated microbiome health solutions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Verb Biotics develops and sells proprietary biotic ingredients, primarily its GABA-producing probiotic LP815 strain and its oat-based Keystone Postbiotic, for use by food, beverage, dietary supplement, and pet health brands. The company focuses on function-first microbiome health solutions supported by clinical trials, computational strain discovery, and whole genome sequencing, and partners directly with brand formulation teams to integrate these ingredients into consumer products.

Product overview

Verb Biotics is a biotic ingredient company offering function-first bioactives for food, beverage, and dietary supplement brands. The portfolio consists of two main ingredient solutions: GABA Probiotic LP815® (a GABA-producing probiotic for mood, stress, and sleep support via the gut-brain axis) and Keystone Postbiotic® (an oat-based postbiotic for foundational gut microbiome health, immune support, and healthy aging). LP815 variants include formulations for general use, women's health, and pets (canine calming). Both products are designed to deliver specific mechanisms of action backed by clinical validation.

Differentiator

Problem solved

Functional benefit

Products and services

• GABA Probiotic LP815 A proprietary GABA-producing probiotic strain (Lactiplantibacillus plantarum LP815) that delivers sustained release of gamma-aminobutyric acid (GABA) through the gut-brain axis for mood, stress, and sleep support. Supplied as an ingredient to food, beverage, dietary supplement, and pet brands. Clinically validated in 139-participant double-blind, randomized, placebo-controlled trial showing significant improvements in sleep quality and stress reduction.
• Keystone Postbiotic A clinically validated, food-first oat-based postbiotic produced through precision fermentation using Lactiplantibacillus and Lacticaseibacillus strains. Designed to improve microbial diversity, support intestinal barrier integrity, deliver keystone bacteria enrichment and metabolite-driven benefits such as butyrate production, and address emotional wellness, immune function, and healthy aging. Supplied as an ingredient to supplement and functional food and beverage brands.
• LP815 for Pets A version of the LP815 GABA-producing probiotic ingredient formulated for canine anxiety and aggression support, designed for daily inclusion in pet calming treats, meal toppers, powdered supplements, and functional kibble. GRAS, Non-GMO Project Verified, and allergen-free certified for use in dog products.
• LP815 for Women A GABA Probiotic LP815 formulation targeted at women's health, focused on tension and sleep support, including applications addressing the gut-brain-hormone axis during hormonal transitions and menopause symptoms. Supplied as an ingredient to women's wellness supplement brands.

Quantifiable outcome

• 77.3% of participants showed at least 4-point improvement in sleep by week 6 with LP815
• +4 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• OpellacoreStrategic or Co-development Partner · 12 March 2026Opella and Verb Biotics announced a partnership focused on gut health solutions. Opella is a consumer healthcare company. This collaboration represents a significant commercial partnership for Verb Biotics to reach broader markets through Opella's distribution and brand reach.
• Professor Siobhain O'MahonyminorStrategic or Co-development Partner · 27 October 2025Professor Siobhain O'Mahony from University College Cork spoke at SupplySide Global 2025 on the gut-brain-hormone axis in menopause. Her research emphasizes the importance of microbiome science in women's health and hormonal transitions. This collaboration positions Verb Biotics in the women's health space and supports scientific credibility around LP815 applications for hormonal wellness.
• YSPOPIA BiosciencecoreOEM/ Whitelabel/ Licensing Partner · 13 June 2023Verb Biotics acquired YSPOPIA Bioscience health and wellness strains, expanding its portfolio of probiotic and biotic ingredients. This acquisition added to Verb's strain library and intellectual property around health and wellness applications.
• People SciencecoreStrategic or Co-development PartnerPeople Science conducted the remote/decentralized clinical trial for LP815 evaluating sleep and stress outcomes in adults with sleep disturbances. The 9-week trial involved 139 participants and confirmed biological activity through increased urinary GABA levels. This partnership enabled Verb to conduct rigorous clinical validation of its GABA-producing probiotic.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Chr. Hansen: Global leader in probiotic cultures and fermented ingredients for food, beverage, and supplement brands. Directly comparable B2B ingredient supplier with extensive strain library, clinical documentation, and brand customer base.
• Ganeden (Kerry Group): Probiotic ingredient supplier (GanedenBC30) sold to food, beverage, and supplement brands. Acquired by Kerry Group, providing direct peer comparison for branded probiotic ingredient commercialization.
• BIO-CAT: Probiotic strain development and ingredient supplier serving CPG brands with clinically supported probiotic solutions. Closely comparable in scale and B2B go-to-market approach.
• Pendulum Therapeutics: Microbiome company with clinically validated probiotic formulations targeting metabolic and gut-brain health. Comparable in clinical validation emphasis and gut-brain axis positioning.
• Winclove Probiotics: European probiotic ingredient developer and supplier specializing in clinically documented multi-strain formulations for B2B customers. Similar B2B ingredient supplier model with clinical claims focus.
• Lallemand Health Solutions: Probiotic manufacturer and supplier serving supplement, food, and functional nutrition brands globally. Direct comparable in B2B probiotic ingredient sales with clinical documentation emphasis.

Broad incumbents

• IFF Health & Biosciences (Dupont Nutrition): Large ingredient conglomerate offering probiotic cultures (HOWARU) and postbiotics as part of broader health ingredient portfolio. Competes with Verb across food, beverage, and supplement channels.
• ADM (PanGard, Biopolis): Global ingredient supplier with growing microbiome and postbiotic offerings. Provides competing scale and integrated supply chain advantages across CPG channels.
• Novonesis (Novozymes-Chr. Hansen merger): Combined enzymes/microorganisms giant created by Novozymes-Chr. Hansen merger in 2024. Largest scale competitor in food and supplement microbial ingredients globally.

Emerging players

• Seed Health: Microbiome-focused consumer brand with proprietary probiotic formulations for gut and broader health. Comparable emphasis on clinical evidence and function-led positioning, though operating consumer-facing rather than B2B ingredient model.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/verb-biotics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verb Biotics